Foley & Lardner LLP released Antibody Drug Conjugates Keep Growing: What You Need to Know, a guide that answers many business and legal questions about the rapid expansion of this area of technology.
Licensing deals for antibody drug conjugates (ADCs), a class of chemotherapy medicines used in the treatment of cancers, are on the rise and worldwide ADCs sales are projected to reach US$20-30 billion per year in the near future. These drugs combine an antibody and cancer treating drug to minimize the impact of chemotherapy on healthy tissue, while maximizing their impact on the cancer, to reduce the overall negative impact on a patient.Although ADCs have been used for more than two decades, continued development of the technology has given regulators, pharmaceutical companies, and doctors more confidence in the clinical efficacy of these treatments, but has also raised more questions. Companies now need to know how to navigate a myriad of concerns related to ADCs/antibody therapeutics, including deals and licensing requirements, patent/IP challenges, and issues related to clinical trials, FDA/regulations, and litigation.With more investments from the pharmaceutical industry and more than 140 new ADCs currently in clinical development, companies touching this space should keep current on the progresses being made and how their businesses may be affected. This guide unpacks the most pertinent questions and issues, with articles including:Antibody Drug Conjugates: An FDA PerspectiveStrategies For Patenting Antibody-Drug Conjugate InventionsDeals and Licensing for Antibody-Drug ConjugatesAntibody-Drug Conjugate LitigationClinical Trial Issues for Antibody Drug Conjugates/Antibody.
Original source can be found here.